IGFBP7 and Sepsis: More recently, urinary TIMP2 and IGFBP7 were identified as biomarkers for AKI, and NephroCheck, based on the arithmetic product of the urinary concentrations of TIMP2 and IGFBP7, has been approved by the US FDA as a biomarker test for AKI diagnosis (1, 2, 32) The increase of urinary TIMP2 and IGFBP7 in AKI mainly results from increased glomerular filtration and decreased tubular reabsorption, but sepsis or endotoxemia does not increase glomerular filtration or induce overt tubular damage, making urinary TIMP2 and IGFBP7 less sensitive in detecting septic AKI (32).